The complaint challenges Oura's marketed claim of "up to 95% accuracy" for sleep-stage tracking compared with clinical polysomnography. It describes the ring's stage estimates as closer to "a coin flip's chance" of being correct, an allegation rather than a proven finding (TechRepublic).

To support that claim, the complaint cites a 2025 Nature study involving 45 nights that it says found roughly 53% overall agreement in sleep-stage classification, treating that gap as its central evidence of deception (TechRepublic).

Bloomberg Law's summary of the filing lays out the legal theory: Oura allegedly "falsely advertised" its rings as able to measure sleep-cycle quality, a measurement the complaint argues requires brain-activity and eye-movement data the ring never collects (Bloomberg Law). That's the plaintiff's framing of what "measuring sleep quality" requires, not an independently established standard.

Oura disputes the suit outright. TechRepublic reported that an Oura spokesperson told TechCrunch, "We stand behind our science, research, and accuracy claims," and that a company spokesperson separately told USA Today Oura "dispute[s] the allegations in this complaint and intend[s] to defend against them" (TechRepublic).

Both numbers, the 95% and the 53%, get treated in the complaint as if they answer the same question. Whether they actually do depends on what each one measures, and that's where the case gets complicated.

Polysomnography defines sleep stages using scalp electrodes and facial sensors that track brain waves and eye movement. Oura's ring has none of that hardware; it infers stages instead from heart rate, heart-rate variability, movement, breathing, and skin temperature (TechRepublic; Bloomberg Law).

That difference in sensing matters, because "accurate" can mean several different things for a sleep device. It can mean correctly telling whether someone is asleep or awake. It can mean correctly classifying which stage a person is in during a specific window of the night. Or it can mean correctly estimating total minutes spent in each stage across an entire night, on average. A device can perform well at one of these and poorly at another, which is precisely the ambiguity the Oura sleep tracking accuracy lawsuit is built around.

Oura draws its own line here. The company says the ring is not a medical device and isn't a substitute for a clinical sleep study, and it points to more than 1,200 nights of validation data behind its algorithm, along with what it describes as multiple independent studies benchmarking the ring against polysomnography (TechRepublic).

None of that settles which of the three measures Oura's 95% figure describes, or which one the cited 53% figure covers. That distinction is exactly what independent research needs to sort out, and the record here only gets partway there.

The clearest independent data available comes from a 2024 study in the journal Sensors, which tested five consumer trackers, including Oura, against research-grade actigraphy and polysomnography in 53 adults over one night in a lab setting (Sensors, 2024).

The results cut both ways. Every device except one, the Garmin Vivosmart, estimated total sleep time about as well as research-grade actigraphy, and bias in REM-sleep estimates was low across all five devices tested (Sensors, 2024).

Deep sleep and light sleep told a different story. Oura specifically underestimated light sleep, and while its deep-sleep bias sat in the middle of the pack, other devices swung further, overestimating shorter deep-sleep periods and underestimating longer ones (Sensors, 2024). Every device also overestimated shorter wake periods overnight and underestimated longer ones, a pattern the study's authors described as systematic bias with real implications for how much these numbers should be trusted (Sensors, 2024).

The researchers behind that study opened their paper with a warning that applies directly to this case: consumer sleep-tracking technology has advanced faster than the science needed to validate it (Sensors, 2024). That's not a verdict on Oura specifically. It's a description of the exact gap a federal court is now being asked to weigh in on.

The Nature study the lawsuit leans on for its 53% figure is known here only through the complaint and secondhand reporting; its scoring method, device version, and participant details aren't independently confirmed in the available record (TechRepublic). A 53% overall agreement figure isn't automatically comparable to a marketed 95% accuracy claim unless the two were calculated the same way, and nothing in the current reporting confirms they were.

The complaint's theory depends on whether Oura disclosed what its accuracy figure measured and how it was calculated: against what benchmark, in what population, and whether the result reflects one night or an average across many. Those are the distinctions this filing forces into the open.

Oura competes with WHOOP, Apple Watch, and other wearables that make similar sleep-tracking promises, according to USA Today. The available reporting doesn't detail how those competitors phrase their own accuracy claims, so no direct comparison can be drawn from the record here.

If Oura loses this fight, or settles on terms that force clearer disclosure, the ripple effect won't stop at one ring. Every wearable maker selling a sleep-quality promise built on a single headline percentage will have reason to look at its own fine print before a plaintiff's firm does it for them.

The complaint is a filing, not a finding. Its allegations haven't been tested in court, and Oura has said it will defend its science (TechRepublic).

What independent research supports is narrower than either side's framing suggests. The 2024 Sensors study found several sleep measures, like total sleep time and REM timing, tracked reasonably close to lab-grade methods, which cuts against the lawsuit's "coin flip" characterization (Sensors, 2024). But that same study found systematic bias in wake time, light sleep, and deep sleep across every device tested, including Oura, which cuts against a blanket 95% accuracy claim just as clearly (Sensors, 2024).

Neither finding resolves the actual question the lawsuit poses: whether Oura's ring can correctly classify which stage someone is in during a given window of a given night. That's a narrower, harder test than either total-sleep-time accuracy or a marketing headline can settle on its own, and it's the piece the current record doesn't answer.

That leaves a practical distinction for anyone wearing one of these rings. Treating it as a reasonable tool for spotting patterns over weeks or months is well supported. Treating a single night's REM or deep-sleep readout as clinical fact is a bigger claim than the current science, or Oura's own disclaimers, actually back. Whatever the court eventually decides, the more immediate question is whether Oura, or its competitors, start qualifying their own sleep-stage claims before they face the same argument in a filing of their own.